A new antihypertensive drug ameliorate insulin resistance

Abstract

Insulin resistance (IR) is defined as decreased sensitivity and/or responsiveness to insulin that promote glucose disposal. A growing body of clinical and epidemiologic evidence indicates that essential hypertension and IR often coexist1. Approximately 50 percent of patients with hypertension can be considered to have IR and hyperinsulinemia1. This inextricable linkage between hypertension and IR has been identified to increase the prevalence of cardiovascular disease (CVD) and new onset of type II diabetes that is the major cause of morbidity and mortality in this clinical syndrome2. However, the driving force linking IR and hypertension remains to be fully elucidated.